Table 2.
ATG5 | BECN1 | LC3B | ||||
---|---|---|---|---|---|---|
Negative, n (%) | Positive, n (%) | Negative, n (%) | Positive, n (%) | Negative, n (%) | Positive, n (%) | |
T stage | ||||||
1-2 | 20 (39.2) | 31 (66.7) | 14 (28.0) | 36 (72.0) | 8 (16.3) | 41 (83.7) |
3 | 46 (33.8) | 90 (66.2) | 46 (30.9) | 103 (69.1) | 43 (27.9) | 111 (72.1) |
4 | 15 (33.3) | 30 (33.7) | 10 (22.2) | 35 (77.8) | 12 (26.1) | 34 (73.9) |
P | 0.578 | 0.444 | 0.152 | |||
N stage | ||||||
0 | 38 (38.0) | 62 (62.0) | 35 (34.0) | 68 (66.0) | 28 (25.9) | 80 (74.1) |
1 | 25 (35.2) | 46 (64.8) | 23 (29.9) | 54 (70.1) | 21 (27.6) | 55 (72.4) |
2 | 18 (29.5) | 43 (70.5) | 12 (18.8) | 52 (81.3) | 14 (21.5) | 51 (78.5) |
P | 0.290 | 0.044 | 0.695 | |||
Distant metastasis | ||||||
No | 68 (38.2) | 110 (61.8) | 57 (30.0) | 133 (70.0) | 49 (25.0) | 147 (75.0) |
Yes | 13 (24.1) | 41 (75.9) | 13 (24.1) | 41 (75.9) | 14 (26.4) | 39 (73.6) |
P | 0.056 | 0.396 | 0.833 | |||
Stage | ||||||
I | 14 (37.8) | 23 (62.2) | 11 (30.6) | 25 (69.4) | 6 (16.7) | 30 (83.3) |
II | 22 (40.7) | 32 (59.3) | 23 (39.0) | 36 (61.0) | 20 (31.3) | 44 (68.8) |
III | 32 (36.8) | 55 (63.2) | 23 (24.2) | 72 (75.8) | 23 (24.0) | 73 (76.0) |
IV | 13 (24.1) | 41 (75.9) | 13 (24.1) | 41 (75.9) | 14 (26.4) | 39 (73.6) |
P | 0.104 | 0.122 | 0.761 | |||
Histology | ||||||
Tubular | 72 (35.0) | 134 (63.0) | 60 (27.8) | 156 (72.2) | 55 (25.0) | 165 (75.0) |
Others† | 9 (34.6) | 17 (65.4) | 10 (35.7) | 18 (64.3) | 8 (27.6) | 21 (72.4) |
P | 0.976 | 0.382 | 0.763 | |||
Lymphovascular invasion | ||||||
Negative | 33 (37.9) | 54 (62.1) | 30 (33.7) | 59 (66.3) | 24 (26.1) | 68 (73.9) |
Positive | 48 (33.1) | 97 (66.9) | 40 (25.8) | 115 (74.2) | 39 (24.8) | 118 (75.2) |
P | 0.455 | 0.189 | 0.827 | |||
Histological grade | ||||||
Well/moderately | 66 (33.5) | 131 (66.5) | 53 (26.0) | 151 (74.0) | 49 (23.4) | 160 (76.6) |
Poorly | 15 (42.9) | 20 (57.1) | 17 (42.5) | 23 (57.5) | 14 (35.0) | 26 (65.0) |
P | 0.285 | 0.035 | 0.124 |
*Statistically significant (P < 0.05).
†Mucinous carcinoma (n = 28), signet-ring-cell carcinoma (n = 2).